Drug intelligence / Profile preview

ONE-001

Development stage: Preclinical
Lead developer: Oncology One
Modality: Small Molecules

Overview

ONE-001 is a preclinical-stage drug candidate being developed by Oncology One, an Australian biotechnology company. As the lead program in the company's pipeline, ONE-001 is currently undergoing preclinical evaluation for the treatment of cancer. However, as of mid-2024, Oncology One has not publicly disclosed the specific biological target, mechanism of action, or the particular cancer indications being targeted. Given the company's specialized focus on small molecule drug discovery, ONE-001 is likely a small molecule inhibitor designed to address high-unmet-need oncological targets.

Beyond the preview

Go deeper on ONE-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONE-001.

Explore the full profile